Chicago, USAJune 28-30, 2018

PREVENTING CARDIOEMBOLIC STROKE AS AN INTERDISCIPLINARY TEAM

hbs.kenes.com

THE

SYMPOSIUM

The Core ORGANIZING COMMITTEE

ChairProf. Natan Bornstein, Israel Tel-Aviv University, Sackler Faculty of Medicine

Prof. Marc Fisher, USAHarvard Medical School

Prof. Chris Granger, USA Duke University School of Medicine

Prof. Jonathan Halperin, USAMount Sinai Medical Center

M.D. Ayrton Massaro, BrazilHospital Sirio Libanes

Prof. Ralph L. Sacco, USAMiller School of Medicine, University of Miami

Prof. Jeffrey Saver, USA Geffen School of Medicine at UCLA

hbs.kenes.com

There won’t be another US meeting like it in 2018!

The Heart & Brain Symposium offers a comprehensive guide

to primary and secondary cardioembolic stroke prevention and other

heart-brain conditions.

Cardiologists and neurologists will benefit from a dedicated meeting on the most up-to-

date knowledge and tools they need as physicians, which they

could not usually get at large cardiology, neurology or

stroke conferences.

Highlights will include interactive case studies on complicated patients that

requires teamwork across the cardiology and neurology

departments - including PFO, ablation and occluders - as well as debates on treatment where

there is a lack of clear guidelines.

· Gain practical tools to use in your daily practice.

· Meet and ask YOUR questions to THE top speakers in the field.

· Present your latest research at a dedicated forum.

· Be part of a unique coming together of cardiologists and neurologists.

CONFIRMED SPEAKERS includeGregory Albers Director, Stanford Stroke Center, USA

Wolfram Doehner Vice Chair of the ESC Council on Stroke, Germany

Philip B. GorelickExecutive Medical Director, Mercy Health Hauenstein Neurosciences,USA

Jeff Healey Director of Arrhythmia Services, Hamilton Health Sciences, USA

Hooman Kamel Director of the Clinical and Translational Neuroscience Unit in the Feil Family Brain and Mind Research Institute at Weill Cornell Medical College, USA

hbs.kenes.com

We look forward to gathering togetherin Chicago, usa!

Late-Breaking Abstract Submission Deadline: April 26, 2018Early Registration Deadline: April 11, 2018

JOIN US in CHICAGO to

PROGRAM HIGHLIGHTS

KEYNOTE LECTURES• THE HEART FAILURE PATIENT WITH STROKE - WHAT IS IMPORTANT,

WHAT IS DIFFERENT?Wolfram Doehner, Vice Chair of the ESC Council on Stroke; Univ.-Prof. for Interdisciplinary Stroke Research Charite, Germany

• NAVIGATE ESUS TRIAL: WHAT DID WE LEARN?Robert Hart, McMaster University, Canada

• ATRIAL FIBRILLATION AND STROKE: THE FIRST 100 YEARSRobert Hart, McMaster University, Canada

SYMPOSIAATRIAL FIBRILLATION – DETECTION, ASSESSING THE RISK AND TREATMENT

25%-30% of all ischemic strokes are of cardio-embolic origin where 45% are related to Atrial Fibrillation (AF). Strokes due to AF are devastating ones with high rates of mortality and disability. Therefore, detecting AF, assessing the stroke risk and tailoring the right preventive treatment to an individual patient is extremely important. This session will highlight and discuss all these important issues. Advances in Detection of AF

• Advances in Detection of AF James Reiffel, Columbia University, USA

• Assessing Stroke Risk in Subjects with AF Hooman Kamel, Weill Cornell Medical Center, USA

• Stroke Prevention in AF: The Role of Target-Specific Oral Anticoagulants Jonathan Halperin, Mount Sinai Medical Center, USA

ATRIAL CARDIOMYOPATHY

Although AF is the widely discussed issue of cardio-embolic strokes other pathological conditions of the left atrium may be important as a source of embolism. This symposium will shed light on the so far "neglected" topic in cardio-embolic stroke.

• Atrial Cardiomyopathy Diagnostic Approaches David Tirschwell, University of Washington Medicine Comprehensive Stroke Center, USA

• Fibrotic Atrial Cardiomyopathy Jeffrey Goldberger, University of Miami Hospital, USA

• The Role of LAA Occlusion Devices in Stroke Prevention in Patients with AF Vivek Reddy, Director of Electrophysiology Laboratories at he Mount Sinai Medical Center, USA

COGNITION AND THE HEART

Cognitive impairment due to vascular pathology of the brain- Vascular Cognitive Impairment (VCI) is an important issue. Understanding the underlying and the related risk factors of VCI as well as the effect of the heart on VCI may have an impact on prevention and treatment of this condition. This symposium will discuss this issue from various aspects.

• The Neurovascular Unit and Cognitive Impairment Constantino Iadecola, Feil Family Brain and Mind Research Institute, USA

• Hypertension, Small Vessel Disease and Cognition Ralph Sacco, Miller School of Medicine, University of Miami, USA

• Defining Optimal Brain Health in Adults Philip Gorelick, Mercy Health Hauenstein Neuroscience Center, USA

• Aortic Stenosis, TAVR and Cognition: Imaging and Clinical FindingsRonald Lazar, University of Alabama at Birmingham, USA

AF AND ICH

Anticoagulants (AC) are the treatment of choice for stroke prevention in AF patients. However, AC carries a risk of bleeding and especially of Intra-Cerebral Hemorrhage (ICH). Therefore, stroke prevention, acute stroke treatment of AF patients with Mechanical Thrombectomy and when to resume AC after ICH is of a major concern for the treating physician. This symposium will try to clarify these complex and problematic issues.

• Stroke Prevention in AF patients at High ICH Risk - Definition and Problems with Medical Management Edip Gurol, Harvard Medical School, USA

• Reversal Agents John Eikelboom, McMaster University, Canada

• Perils of Combination Anticoagulant and Antiplatelet Therapy Edip Gurol, Harvard Medical School, USA

• Resuming Anticoagulation after ICH Larry Goldstein, University of Kentucky, USA

ATRIAL FIBRILLATION: 3 IMPORTANT ASPECTS

There are several practical aspects in the treatment of AF patients with AC. This session will deal with three of these important topics as listed below:

• How to Improve the Use of Anticoagulation for Stroke Prevention in AFChristopher Granger, Duke University School of Medicine, USA

• When to Start Anticoagulation after Acute Ischemic Stroke Natan Bornstein, Shaare Zedek Medical Center, Jerusalem, Israel

• Treatment of Acute Stroke in AF Patients with Mechanical ThrombectomyGregory Albers, Stanford Stroke Center, USA

PROGRAM HIGHLIGHTS

EMBOLIC STROKE OF UNDETERMINED SOURCEStroke due to ESUS imposes difficult clinical dilemma for the treating physician. The magnitude of the problem, practical evaluation and treatment options will be discussed in this symposium.

• The Magnitude of the Problem Georgios Tsivgoulis, University of Athens School of Medicine/The University of Tennessee Health Science Center, Greece/USA

• Evaluation of Patients with ESUS Jeffrey Saver, Geffen School of Medicine at UCLA, USA

• Treatment options Gustavo Saposnik, University of Toronto, Canada

DEBATE SESSIONSPFO – WHO TO CLOSE?Until recently PFO closure by endovascular procedure was not generally recommended. However, recently the results of 2 RTCs (CLOSE and REDUCE) and the long-term follow-up of the RESPECT trial were published. These results will have an impact on the current practice. The question now is not "should we close"? but "who to close"? This will be the scope of this debate.

1st Debater: Brett Cucchiara, University of Pennsylvania, USA2nd Debater: Richard Smalling, UTHealth and Memorial Hermann Heart and Vascular Institute, USA

THE BURDEN OF AF TO TRIGGER TREATMENTIt is greatly accepted that patients with Embolic Stroke of Unknown Source (ESUS) should go on long-term cardiac monitoring in order to detect sub-clinical AF. However, it is still unknown what is the burden of AF that is clinically relevant to trigger treatment with anticoagulants. This debate will highlight the various opinions: "small vs. extensive" is the dilemma that will be discussed.

The Burden of AF to trigger treatment

1st Debater: Jeff Healey, McMaster University, Canada2nd Debater: Rod Passman, Northwestern Memorial Hospital, USA

DISCUSSIONSCOLLABORATIVE MEDICINE

• Wolfram Doehner, Vice Chair of the ESC Council on Stroke; Univ.-Prof. for Interdisciplinary StrokeResearch Charite, Germany

• James Klaas, Assistant Professor of Neurology, Mayo Clinic, Rochester, USA

• Christopher Granger, Duke University School of Medicine, USA

PROGRAM HIGHLIGHTS

INTERACTIVE CASE DISCUSSION

• Shadi Yaghi, Brown University, USA

• MingMing Ning, Harvard Medical School, USA

• Kevin Sheth, Yale School of Medicine, USA

• Eitan Auriel, Carmel Medical Center, Israel

EDUCATIONAL SESSIONBRAIN RECOVERY AFTER STROKE

Medical Therapy for Post-Stroke Motor Recovery• Natan Bornstein, Shaare Zedek Medical Center, Jerusalem, Israel

Intracardiac Hemostasis Parameters, Endothelial Damage and Their Association with Microembolization in the Fibrillating Atrium

• Laszlo Csiba, University Debrecen, Hungary

Neuroprotection in the Reperfusion Era• Jeffrey Saver, Geffen School of Medicine at UCLA, USA

View the full program here.

PROGRAM HIGHLIGHTS

THE

SYMPOSIUM